| Overview |
| bs-11193r-pe-100ul |
| NSMase2 Polyclonal Antibody, PE Conjugated |
| IF |
| Human, Mouse, Rat |
| Specifications |
| PE |
| Rabbit |
| KLH conjugated synthetic peptide derived from human NSMase2 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| N-SMase2; Cca1; neutral sphingomyelinase 2; Confluent 3Y1 cell-associated protein 1; Neutral sphingomyelinase 2; Neutral sphingomyelinase II; NSMA2_HUMAN; nSMase-2; nSMase2; Smpd3; Sphingomyelin phosphodiesterase 3. |
| N-SMase2 (neutral sphingomyelinase 2), also known as NSMASE2 or SMPD3 (sphingomyelin phosphodiesterase 3), is a ubiquitously expressed 655 amino acid member of the magnesium-dependent phosphohydrolase protein family. Localized to the membrane of the Golgi apparatus, N-SMase2 functions to catalyze the hydrolysis of sphingomyelin to form ceramide and phosphocholine—two proteins that mediate cell growth arrest and apoptosis. N-SMase2 is enzymatically activated by unsaturated fatty acids and phosphatidylserine and, through regulation of ceramide synthesis, is involved in growth suppression and postnatal development. Expression of N-SMase2 is upregulated during the G0/G1 phases of the cell cycle and optimal N-SMase2 activity occurs at a slightly basic pH of 7.5. N-SMase2 deficiency is the cause of chondrodysplasia, a genetic disorder characterized by impaired bone growth that leads to short stature, bowlegs and underdeveloped joints. |
| Application Dilution |
| IF |
1:100-500 |
Powered by Bioz